Drug Trial Radar · NCT06215846
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
12
Planned (sponsor's estimate)
Start
May 7, 2024
Primary completion
May 30, 2026
Study completion Jun 28, 2026
Sponsor
- Lead sponsor
- Beijing Bio-Targeting Therapeutics Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 open-label study to evaluate the safety, tolerability, and pharmacokinetics of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) at dose of 5×10∧9VP、5×10∧10VP、5×10∧11VP in Patients With Malignant Solid Tumors. Subjects will be treated with a single dose of BioTTT001 Injection after the screening period.
Conditions
- Solid Tumor
Interventions
BioTTT001 injectionBiological
BioTTT001 is administered as a single Intratumoral injection. The dose groups to be infusion were 5×10\^9 VP, 5×10\^10 VP and 5×10\^11 VP based on the 3+3 dose escalation principle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: 28 days within BioTTT001 injection
- MTDTime frame: 28 days within BioTTT001 injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of China Medical Univeristy
Shenyang, Liaoning, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.